Edition:
India

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

16.62EUR
17 Jan 2020
Change (% chg)

€0.12 (+0.73%)
Prev Close
€16.50
Open
€16.50
Day's High
€16.85
Day's Low
€16.27
Volume
33,887
Avg. Vol
55,416
52-wk High
€18.35
52-wk Low
€8.55

Summary

Name Age Since Current Position

Andre Choulika

2000 Chairman of the Board, Chief Executive Officer, Member of the Executive Board

Eric Dutang

Chief Financial Officer, Member of the Executive Committee

Bill Montelth

2019 Executive Vice President of Technical Operations, Member of the Executive Committee

David Sourdive

2019 Executive Vice President, Strategic Initiatives, Member of the Executive Committee

Jon Voss

2019 Executive Vice President, Member of the Executive Committee

Stephan Reynier

Chief Regulatory and Compliance Officer, Member of the Executive Committee

Francisco Esteva

2019 Vice President, Clinical Development

Marie-Bleuenn Terrier

2013 General Counsel, Member of the Executive Committee

Philippe Duchateau

2012 Chief Scientific Officer, Member of the Executive Committee

Laurent Arthaud

2011 Non-Executive Independent Director

Pierre Bastid

2011 Non-Executive Independent Director

Rainer Boehm

58 2017 Non-Executive Independent Director

Alain Godard

72 2007 Non-Executive Independent Director

Herve Hoppenot

59 2017 Non-Executive Independent Director

Annick Schwebig

2011 Non-Executive Independent Director

Biographies

Name Description

Andre Choulika

Dr. Andre Choulika is one of the founders of Cellectis SA and has been Chairman of the Board, Member of the Executive Committee and Chief Executive Officer since 2000. He has also been Chairman of Calyxt (previously Cellectis plant sciences) since August 2010. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was a pioneer in the analysis and use of meganucleases to modify complex genomes. He also served on the Boards of Directors of several biotechnology companies. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. Dr. Choulika also has management training from the HEC (Challenge +).

Eric Dutang

Mr. Eric Dutang serves as Chief Financial Officer and Member of the Executive Committee of Cellectis SA. Certified Public Accountant in France, joined Cellectis as Deputy Chief Financial Officer in May 2015. He began his career as financial auditor with KPMG, first in Paris for five years and then in New York for two years. He worked for publicly-traded companies in France and the U.S. including Vivendi, Veolia Environnement, and Cablevision. He then became a member of the transactions and advisory teams in Paris for seven years where he carried out acquisitions/disposals for both publicly-traded companies and private equity funds. After serving at KPMG, he worked on international business developments for French publicly-traded groups, including Air Liquide and Thales. Mr. Dutang holds a Master of Finance and Executive MBA from HEC Paris (France)/Babson Massachusetts (USA).

Bill Montelth

Mr. Bill Montelth has been Executive Vice President of Technical Operations and Member of the Executive Committee at Cellectis SA since July 2019. He joined company in 2018 as Senior Vice President US Manufacturing. Before joining Cellectis, Mr. Monteith was the Chief Operating Officer for Hitachi Chemical Advanced Therapeutic Solutions (formerly PCT). While at Hitachi, He was part of the executive team overseeing the merger with Hitachi and went on to build a cell and gene therapy facility in Yokohama Japan in addition to being responsible for the US based facilities in Allendale New Jersey and Mountain View California. Prior to that, Mr. Monteith was the VP and General Manager, and then Executive VP, Technical Operations, for Dendreon which was the first autologous cellular therapy to get approval in the United States. He has also held leadership roles at Sandoz, Shire, and Wyeth pharmaceuticals, ranging from technical operations to quality assurance. Mr. Monteith received his Bachelor of Science in pre-medical studies with a major in Chemistry from Saint Lawrence University in Canton, NY.

David Sourdive

Dr. David J.D. Sourdive serves as Executive Vice President, Strategic Initiatives, Member of the Executive Committee at Cellectis SA. He previously served as Director, Executive Vice President Technical Operations, Member of Executive Committee and Deputy Chief Executive Officer at the company as of 2016. Previously he served as Company's Executive Vice President-Corporate Development and Director. From 2014, Dr. Sourdive also served on the Board of Directors of Mediterranean Institute for Life Sciences. He previously served on the Board of Directors of Medicen Paris Region and Seine Saint Denis Avenir. From 1998 to 2000, he directed the biotechnologies laboratory of the Centre d’Etudes du Bouchet for the French Ministry of Defense. Dr. Sourdive graduated from the Ecole Polytechnique and received his Ph.D. in molecular virology at the Institut Pasteur. He also has management training from the HEC (Challenge +). He is currently on the Board of Directors within MEDILS, Eukarys SAS and Omics SAS.

Jon Voss

Mr. Jon Voss has been Executive Vice President of Global Quality and Member of the Executive Committee at Cellectis SA since July 2019. . Mr. Voss has over 30 years of US and international Quality expertise in gene therapy, small molecule, biologic and medical device products working as VP of Quality for such companies as Generation Bio, Sarepta Therapeutics and Genzyme. Having worked in early stage pre-clinical, clinical and commercial organizations, Mr. Voss has unique experience in moving companies from the development to commercial stage. As EVP of Global Quality, Mr. Voss is building the Cellectis global quality organization to support the existing Cellectis UCART clinical programs as well as ensuring that Cellectis is prepared for commercial licensure and the associated operations. Mr. Voss earned his Bachelor of Science degree from the University of California at Davis and received his Master of Science in Biomedical Engineering from Boston University.

Stephan Reynier

Mr. Stephan Reynier serves as Chief Regulatory and Compliance Officer and Member of the Executive Committee at Cellectis SA. He joined Cellectis in April 2011. r is in charge of ensuring a speedy and successful development of the UCART product family by establishing close interactions with regulatory agencies such as EMA and FDA, while securing compliance to applicable regulations, regulatory guidelines and quality assurance standards. Mr Reynier has extensive experience, from his previous positions as Senior Director at Voisin Consulting Life Sciences and European Associate Director Medical Affairs at Gilead Sciences, in the design and implementation of regulatory strategies for the development of drugs and biologics, with a strong focus on cell and gene therapy. Mr Reynier graduated as Agro-Engineer in France and received a Master of Science in Chemical Engineering from the University of Toronto, Canada.

Francisco Esteva

Mr. Francisco Esteva is Vice President, Clinical Development of the Company. He is responsible for overseeing U.S. medical activities and works with the Clinical Operations team to supervise and ensure the safety of clinical trials. Dr. Esteva currently serves as Adjunct Professor at NYU School of Medicine. He was most recently Director of Breast Medical Oncology and Associate Director of Clinical Investigation at NYU Langone Health's Perlmutter Cancer Center, and Professor of Medicine at NYU School of Medicine. Prior to this, he was Professor of Medicine (Oncology) at The University of Texas MD Anderson Cancer Center, where he developed a successful program in translational and clinical research focused on HER2 targeted therapy. His training included MD/PhD degrees from the University of Zaragoza (Spain), a Residency in Internal Medicine at Cooper University Hospital (Camden, NJ) and a Fellowship in Medical Oncology at Georgetown University Medical Center (Washington DC). Dr. Esteva is an international thought leader for innovation in cancer care and clinical research. He is an elected member of the American Society of Clinical Investigation and a Fellow of the American College of Physicians. His research and clinical achievements have contributed to the approval of life-saving therapies in breast cancer.

Marie-Bleuenn Terrier

Ms. Marie-Bleuenn Terrier has been General Counsel and Member of the Executive Committee of Cellectis since 2013. Prior to joining Cellectis, she worked as Legal Counsel for Pfizer from 2004 to 2006, and for Boehringer Ingelheim from 2006 to 2008. She holds a Master’s degree in Law from Universite Paris 1 Pantheon-Sorbonne.

Philippe Duchateau

Dr. Philippe Duchateau has served as Chief Scientific Officer and Member of Executive Committee at Cellectis SA since January 30, 2012. He joined the Company in 2001 and he served as Head of Research Department from 2004. After receiving his Ph.D. in 1993 in biochemistry and molecular biology at the Institut Pasteur (Lille, France), he completed a research fellowship from 1993 to 2001 at the University of California, San Francisco (United States) within the Cardiovascular Research Institute. He is co-inventor of numerous patents in the field of nucleases and gene editing and co-author on more than 50 scientific publications and co-editor of one book entitled Site-directed Insertion of Transgenes.

Laurent Arthaud

Mr. Laurent Arthaud has served as Non-Executive Independent Director of Cellectis SA since October 2011. From 2006 to 2012, Mr. Arthaud held the position of Deputy Chief Executive Officer at CDC Entreprises. From 2009 he also directed InnoBio, an investment fund managed by Bpifrance Investissement as part of the FSI France Investissement program. From 1999 to 2004 he served as Vice President of Aventis Capital, an investment subsidiary of the pharmaceuticals group Aventis, and as President of Pharmavent Partners from 2004 to 2006. Mr. Arthaud is a graduate of the Ecole Polytechnique and the l’Ecole Nationale de Statistique et d’Administration Economique. He is currently on the Board of Directors of Adocia, TxCell, Calyxt Inc. and Aledia, among others.

Pierre Bastid

Mr. Pierre Bastid has served as Non-Executive Independent Director of Cellectis SA since October 2011. He has been Member of the Board of Directors of HOUGOU S.A. since 2011. He also currently serves on the Boards of Directors of HOUGOU Development S.A., Louise 342-344 S.A., Shango S.A., Hebioso S.A., Nepteam S.A.S. and Pharnext SAS. From 2005 to 2011, he served as the President and Chief Executive Officer of Converteam Group S.A.S. (formerly Alstom Power Conversion). From June 2011 to July 2014, he was also a Member of Board of Directors of Zaka S.A. From 2008 to 2011, Mr. Bastid served as President and a Member of the Board of Directors of CVT Holding S.A.S. and as President of Financiere CVT S.A.S. From 2009 to 2011, he served as President of CMC Kilimanjaro, CMC Everest, CMC Mac Kinley, CMC Elbrouz and CMC K2. He graduated from Ecole Centrale de Lyon and INSEAD.

Rainer Boehm

Mr. Rainer Boehm, M.D., has been Non-Executive Independent Director of Cellectis SA since June 26, 2017. Currently, he serves also on the Board of Directors at Nordic Nanovector ASA and Humanigen Inc. He graduated Universitaet Ulm with degree in Medicine as well as Schiller International University with master of business administration degree.

Alain Godard

Mr. Alain Godard has served as Non- Executive Independent Director of Cellectis SA since October 2007. He began his agronomy career in 1967 in Africa as a researcher at the l’Institut de Recherche pour les Huiles et Oleagineux (Institute for Research on Oils and Oleaginous Plants). Since 2002, Mr. Godard has been a consultant in plant biotechnology and management. He has been Manager of SARL Godard & Co, and he also serves on the Board of Directors of Cakyxt Inc. He previously served as Chairman of the Management Board of Aventis Cropscience from 1999 to 2001 and served on the Executive committee of Aventis Cropscience for the same period. He held several executive positions at Rhone-Poulenc Agrochimie since joining in 1975, and he became CEO of the company in 1991 and chairman and CEO in 1995. Mr. Godard was appointed to the executive Committee of the Rhone-Poulenc group in 1997, where he oversaw operations in the field of animal and plant health and the group’s Asia region. In 1999 he was an active player in the merger of Hoechst and Rhone-Poulenc, which resulted in the founding of Aventis. Mr. Godard is a graduate of the Ecole Nationale Superieure Agronomique de Toulouse.

Herve Hoppenot

Mr. Herve Hoppenot has been Non-Executive Independent Director of Cellectis SA since June 26, 2018. Currently, he serves also as Chairman of Incyte Inc.

Annick Schwebig

Dr. Annick Schwebig has served as Non-Executive Independent Director of Cellectis SA since October 2011. In 2000, she founded the French subsidiary of biopharmaceuticals company Actelion. Dr. Schwebig worked as a senior manager at the Bristol-Myers Squibb for 17 years from 1983 to 2000. She is a graduate of the University of Paris Medical School. Currently, she serves on the Board of Directors of Inventiva Pharma and B Cell Design.